Status:
UNKNOWN
Cardiac Adverse Reactions Related to Immune Checkpoint Inhibitor in NSCLC Patients
Lead Sponsor:
Shanghai Chest Hospital
Conditions:
Adverse Reactions
Immune Checkpoint Inhibitor
Eligibility:
All Genders
18-80 years
Brief Summary
This is a prospective, open label, single arm study. A total of 300 patients with primary non-small cell lung cancer treated with PD-1/PD-L1 immune checkpoint inhibitors(ICIs) are expected to included...
Eligibility Criteria
Inclusion
- Be willing and able to provide written informed consent/assent for the trial;
- Lung cancer patients whose pathological results confirmed is primary non-small cell lung cancer, stage III\~IV;
- Patients received with ICIs treatment, including anti-PD-1 or anti-PD-L1 for at least two courses;
Exclusion
- Patients who do not have pathological diagnosis;
- Patients who can't finish the follow-up;
- The anti-PD-1, anti-PD-L1 therapy was less than two courses;
- Patients whose cancer diagnosed with small cell lung cancer.
Key Trial Info
Start Date :
August 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2023
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT04473703
Start Date
August 1 2020
End Date
August 1 2023
Last Update
July 16 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.